Abstract:
Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cmax of a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.
Abstract:
The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel reactive groups attached to linker groups of 2-1000 atoms length. The present invention also contemplates the use of bifunctional bridge molecules to link two or more entities, wherein the functional groups of the bridge molecules are the novel reactive groups of the present invention.
Abstract:
The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel reactive groups attached to linker groups of 2-1000 atoms length. The present invention also contemplates the use of bifunctional bridge molecules to link two or more entities, wherein the functional groups of the bridge molecules are the novel reactive groups of the present invention.
Abstract:
The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel reactive groups attached to linker groups of 2–1000 atoms length. The present invention also contemplates the use of bifunctional bridge molecules to link two or more entities, wherein the functional groups of the bridge molecules are the novel reactive groups of the present invention.
Abstract:
Compounds of the general formula I′ in which R1 is H, C1-C12alkyl; C5-C12cycloalkyl; C2-C18alkyl which is interrupted by one or more O; SR4; OR5; or is a group of formula II or III R2, R21 and R3 independently of one another, are H or —Y-T as defined in claim 1, where T is a reactive group selected from OH, acryl- and methacryloxy and arylcarbonate groups, and further symbols are as defined in claim 1, are effective as crosslinking agents for polymeric networks, especially as in flexographic printing plates, coatings, and plastic containers or films. Further provided is a method of protecting the content of a clear or lightly colored plastic container or film against the deleterious effects of ultraviolet radiation, which method comprises permanently and covalently bonding one or more UV absorbing moieties of a durable s-triazine UV absorber via condensation to a suitable polymer component.
Abstract:
Method for making caprolactam from 6-aminocapronitrile that contains greater than 500 ppm tetrahydroazepine and its derivatives (THA) in which the THA is not removed from the method until after the caprolactam is produced.
Abstract:
본 발명은 락탐 제조 방법에 관한 것이다. 더욱 구체적으로는, 본 발명은 예를 들면 불포화 모노니트릴 화합물, 더욱 특히는 2-, 3- 또는 4-펜텐니트릴과 같은 펜텐니트릴 (이는 단독 또는 혼합물이고, 이하에서 혼합물에 대해서는 PN 으로, 그리고 2PN, 3PN 및 4PN 으로 각각 지칭함)을 원료로서 사용하여 수득된 알킬 시아노발레레이트로부터 락탐을 제조하는 방법에 관한 것이다. 본 발명의 방법은, 알킬아미노카프로에이트의 중간 분리 없어, 알킬 시아노발레레이트를 e-카프로락탐으로 수소화 및 고리화시키는 것을 포함한다.
Abstract:
The invention relates to a lactam production method. More specifically, the invention relates to a method of producing lactams from alkyl cyanovalerate compounds obtained using, for example, unsaturated mononitrile compounds as raw materials and, more particularly, pentenenitriles such as 2-, 3-, 4-pentenenitriles taken alone or in a mixture and hereafter referred to as PN for the mixture and 2PN, 3PN and 4PN respectively. The inventive method comprises the hydrogenation and the cyclization of the alkyl cyanovalerate into e-caprolactam without the intermediate separation of the akylaminocaproate.